Roadzen Reports $13.7 Million Second Quarter Revenue, A 15.2% Improvement Over Prior Year Quarter, And Fifth Consecutive Quarter Of Adjusted EBITDA Improvement
| Roadzen Inc. | ||||
| Unaudited Condensed Consolidated Balance Sheets | ||||
| (in US $, except share count) | ||||
| Particulars | As of September 30, | As of March 31, | ||
| 2025 | 2025 | |||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 4,973,633 | 4,836,576 | ||
| Accounts receivable, net | 2,648,485 | 2,625,385 | ||
| Inventories | 213,875 | 202,535 | ||
| Prepayments and other current assets | 25,913,502 | 19,092,595 | ||
| Investments | 366,487 | 197,805 | ||
| Total current assets | 34,115,982 | 26,954,896 | ||
| Non current assets | ||||
| Restricted cash | 219,746 | 217,064 | ||
| Non marketable securities | 268,764 | 269,470 | ||
| Property and equipment, net | 591,781 | 602,923 | ||
| Goodwill | 2,298,287 | 2,061,553 | ||
| Operating lease right-of-use assets | 1,272,406 | 1,109,219 | ||
| Intangible assets, net | 2,638,248 | 1,243,253 | ||
| Other long-term assets | 144,643 | 120,972 | ||
| Total Non current assets | 7,433,875 | 5,624,454 | ||
| Total assets | 41,549,857 | 32,579,350 | ||
| Liabilities and shareholders' Equity/(Deficit) | ||||
| Current liabilities | ||||
| Current portion of long-term borrowings | 2,831,559 | 2,904,444 | ||
| Short-term borrowings | 20,194,849 | 19,865,645 | ||
| Accounts payable and accrued expenses | 33,237,612 | 30,254,010 | ||
| Derivative warrant liabilities | 1,339,967 | 1,489,818 | ||
| Short-term operating lease liabilities | 463,347 | 318,921 | ||
| Other current liabilities | 3,219,831 | 2,102,466 | ||
| Total current liabilities | 61,287,165 | 56,935,304 | ||
| Non current liabilities | ||||
| Long-term borrowings | 147,874 | 139,775 | ||
| Long-term operating lease liabilities | 413,863 | 628,400 | ||
| Other long-term liabilities | 551,817 | 566,651 | ||
| Total Non current liabilities | 1,113,554 | 1,334,826 | ||
| Total liabilities | 62,400,719 | 58,270,130 | ||
| Commitments and contingencies (refer note 22) | ||||
| Shareholders' Equity/(Deficit) | ||||
| Ordinary Shares and additional paid in capital, $0.0001 par value per share, 220,000,000 shares authorized as of September 30, 2025 and March 31, 2025; 76,021,755, and 74,290,986 shares outstanding as of September 30, 2025 and March 31, 2025 respectively | 99,195,750 | 95,501,291 | ||
| Accumulated deficit | (229,940,316 | ) | (223,826,442 | ) |
| Accumulated other comprehensive income/(loss) | (1,133,485 | ) | (468,859 | ) |
| Other components of equity | 103,853,847 | 103,720,113 | ||
| Total shareholders' deficit | (28,024,204 | ) | (25,073,897 | ) |
| Share Application Money | 1,084,289 | - | ||
| Non-controlling interest | 6,089,053 | (616,883 | ) | |
| Total deficit | (20,850,862 | ) | (25,690,780 | ) |
| Total liabilities and Total Deficit | 41,549,857 | 32,579,350 | ||
| Roadzen Inc. | |||||||||
| Unaudited Condensed Consolidated Statements of Operations | |||||||||
| (in US $, except share count) | |||||||||
| For the three months ended September 30, | For the six months ended September 30, | ||||||||
| Particulars | 2025 | 2024 | 2025 | 2024 | |||||
| Revenue | 13,679,267 | 11,874,098 | 24,544,813 | 20,805,615 | |||||
| Costs and expenses: | |||||||||
| Cost of services | 6,057,579 | 5,217,621 | 10,527,032 | 10,645,061 | |||||
| Research and development | 148,529 | 1,496,600 | 230,063 | 3,286,142 | |||||
| Sales and marketing | 6,252,328 | 8,076,959 | 12,384,339 | 13,879,257 | |||||
| General and administrative | 3,806,801 | 20,430,960 | 6,384,698 | 46,257,148 | |||||
| Depreciation and amortization | 750,207 | 193,372 | 875,206 | 673,721 | |||||
| Total costs and expenses | 17,015,443 | 35,415,512 | 30,401,338 | 74,741,329 | |||||
| Loss from operations | (3,336,176 | ) | (23,541,414 | ) | (5,856,525 | ) | (53,935,714 | ) | |
| Interest expense (net) | (1,249,540 | ) | (626,834 | ) | (2,190,859 | ) | (1,448,520 | ) | |
| Fair value gains/(losses) in financial instruments carried at fair value | 1,067,732 | (1,096,949 | ) | 556,194 | (18,249,009 | ) | |||
| Other income (net) | 1,353,929 | 3,252,528 | 1,306,007 | 3,274,880 | |||||
| Total other income/(expense) | 1,172,121 | 1,528,745 | (328,658 | ) | (16,422,649 | ) | |||
| Loss before income taxes and equity-method investment activity | (2,164,055 | ) | (22,012,669 | ) | (6,185,183 | ) | (70,358,363 | ) | |
| Equity method investment activity, net | |||||||||
| (Loss)/Income before income tax expense | (2,164,055 | ) | (22,012,669 | ) | (6,185,183 | ) | (70,358,363 | ) | |
| Less: income tax (benefit)/expense | 10,826 | (181,264 | ) | 90,805 | (74,614 | ) | |||
| Income tax expense | 15,640 | 4,214 | 50,589 | 17,147 | |||||
| Deferred tax expense | (4,814 | ) | (185,478 | ) | 40,216 | (91,761 | ) | ||
| Net (loss)/income before non-controlling interest | (2,174,881 | ) | (21,831,405 | ) | (6,275,988 | ) | (70,283,749 | ) | |
| Net loss attributable to non-controlling interest, net of tax | (66,777 | ) | (21,366 | ) | (162,114 | ) | (66,685 | ) | |
| Net Loss attributable to Ordinary shareholders | (2,108,104 | ) | (21,810,039 | ) | (6,113,874 | ) | (70,217,064 | ) | |
| Net loss per share attributable to Ordinary shareholders | |||||||||
| Basic and diluted | (0.03 | ) | (0.32 | ) | (0.08 | ) | (1.03 | ) | |
| Weighted-average number of shares used in computing net loss per share | 75,671,838 | 68,440,829 | 75,671,838 | 68,440,829 |
| Roadzen Inc. | |||||
| Unaudited Condensed Consolidated Statements of Cash Flow | |||||
| (in US $, except share count) | |||||
| For the six month ended September 30, | |||||
| Particulars | 2025 | 2024 | |||
| Cash flows from operating activities | |||||
| Net loss per share attributable to Ordinary shareholders | (6,113,874 | ) | (70,217,064 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | 875,206 | 673,721 | |||
| Stock based compensation | 133,734 | 46,977,256 | |||
| Deferred income taxes | (1,263 | ) | (223,516 | ) | |
| Unrealised foreign exchange loss/(profit) | (62,074 | ) | 101,374 | ||
| Fair value losses/(profits) in financial instruments carried at fair value | (556,194 | ) | 18,249,009 | ||
| Expected credit loss (net of reversal) | 25,572 | (112,451 | ) | ||
| Balances written off/(back) | (1,331,258 | ) | (3,200,441 | ) | |
| Net loss attributable to non-controlling interest, net of tax | (162,114 | ) | (66,685 | ) | |
| Changes in assets and liabilities, net of assets acquired and liabilities assumed from acquisitions: | |||||
| Inventories | (11,340 | ) | (20,836 | ) | |
| Income taxes, net | - | - | |||
| Accounts receivables, net | 417,176 | 380,405 | |||
| Prepayments and other assets | (6,073,976 | ) | 2,018,036 | ||
| Accounts payable and accrued expenses | 3,107,114 | (1,554,615 | ) | ||
| Other liabilities | 754,275 | (4,255,358 | ) | ||
| Net cash used in operating activities | (8,999,015 | ) | (11,251,165 | ) | |
| Cash flows from investing activities | |||||
| Purchase of property and equipment, intangible assets and goodwill | (355,635 | ) | 39,443 | ||
| Proceeds from sale of mutual fund | - | 193,606 | |||
| Investment in mutual funds and bonds | (28,213 | ) | - | ||
| Proceeds from forward purchase agreement | - | 1,000,000 | |||
| Net cash used in investing activities | (383,848 | ) | 1,233,049 | ||
| Cash flows from financing activities | |||||
| Proceeds from issue of ordinary shares | 3,694,459 | - | |||
| Proceeds from issue of ordinary shares of subsidiary to the Non-controlling interest | 5,778,944 | ||||
| Net proceeds/(payments) from long term borrowings | (47,093 | ) | - | ||
| Net proceeds/(payments) from short-term borrowings | (894,769 | ) | 4,460,327 | ||
| Net cash generated from financing activities | 8,531,541 | 4,460,327 | |||
| Effect of exchange rate changes on cash and cash equivalents | 62,972 | 2,368 | |||
| Net (decrease)/increase in cash and cash equivalents (including restricted cash) | (788,349 | ) | (5,555,421 | ) | |
| Cash acquired in business combination | 928,074 | - | |||
| Cash and cash equivalents at the beginning of the period (including restricted cash) | 5,053,654 | 11,565,088 | |||
| Cash and cash equivalents at the end of the period (including restricted cash) | 5,193,379 | 6,009,667 | |||
| Reconciliation of cash and cash equivalents | |||||
| Cash and cash equivalents | 4,973,633 | 5,992,238 | |||
| Restricted cash | 219,746 | 17,429 | |||
| Total cash and cash equivalents | 5,193,379 | 6,009,667 | |||
| Supplemental disclosure of cash flow information | |||||
| Cash paid for interest, net of amounts capitalized | 1,707,711 | 885,011 | |||
| Non-cash investing and financing activities | |||||
| Consideration payable in connection with acquisitions | 488,000 | 488,000 | |||
| Interest accrued on borrowings | 2,652,119 | 317,596.86 |
Non-GAAP Financial Measures
This press release includes Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (“Adjusted EBITDA”), a non-GAAP financial measure which excludes the impact of finance costs, taxes, depreciation and amortization and certain other items from reported net profit or loss. We believe that Adjusted EBITDA aids investors by providing an operating profit/loss without the impact of non-cash depreciation and amortization and certain non-recurring and other items to help clarify sustainability and trends affecting the business. For comparability of reporting, management considers non-GAAP measures in conjunction with U.S. GAAP financial results in evaluating business performance. Adjusted EBITDA should not be considered a substitute for, or superior to, the measures of financial performance prepared in accordance with U.S. GAAP. In addition, Adjusted EBITDA does not purport to represent cash flows provided by, or used for, operating activities in accordance with GAAP and should not be used as a measure of liquidity.
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as substitutes for financial information presented under GAAP. There are a number of limitations related to the use of non-GAAP financial measures versus comparable financial measures determined under GAAP. For example, other companies in our industry may calculate these non-GAAP financial measures differently or may use other measures to evaluate their performance. These limitations could reduce the usefulness of these non-GAAP financial measures as analytical tools. Investors are encouraged to review the related GAAP financial measures and the reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures and to not rely on any single financial measure to evaluate our business.
The following table reconciles our net loss reported in accordance with U.S. GAAP to Adjusted EBITDA:
| For the three months ended September 30, | ||||
| Particulars | 2025 | 2024 | ||
| Net loss | (2,108,104 | ) | (21,810,039 | ) |
| Adjusted for: | ||||
| Other (income)/expense net | (1,353,929 | ) | (3,252,528 | ) |
| Interest (income)/expense | 1,249,540 | 626,834 | ||
| Fair value changes in financial instruments carried at fair value(1) | (1,067,732 | ) | 1,096,949 | |
| Tax (benefit)/expense | 10,826 | (181,264 | ) | |
| Depreciation and amortization | 750,207 | 193,372 | ||
| Stock based compensation expense | 62,381 | 20,746,267 | ||
| Non-cash expenses | 132,841 | 351,130 | ||
| Non-recurring expenses | 1,231,747 | 105,725 | ||
| Adjusted EBITDA | (1,092,224 | ) | (2,123,554 | ) |
| For the six months ended September 30, | ||||
| Particulars | 2025 | 2024 | ||
| Net loss | (6,113,874 | ) | (70,217,064 | ) |
| Adjusted for: | ||||
| Other (income)/expense net | (1,306,007 | ) | (3,274,880 | ) |
| Interest (income)/expense | 2,190,859 | 1,448,520 | ||
| Gain on bargain purchase | - | |||
| Fair value changes in financial instruments carried at fair value(1) | (556,194 | ) | 18,249,009 | |
| Tax (benefit)/expense | 90,805 | (74,614 | ) | |
| Depreciation and amortization | 875,206 | 673,721 | ||
| Stock based compensation expense | 133,739 | 46,977,256 | ||
| Non-cash expenses | 439,555 | 636,190 | ||
| Non-recurring expenses | 1,747,849 | 630,483 | ||
| Adjusted EBITDA | (2,498,062 | ) | (4,951,379 | ) |

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment